This page shows the latest ESMO news and features for those working in and with pharma, biotech and healthcare.
At last year’s European Society for Medical Oncology (ESMO) congress, Bristol-Myers Squibb’s Opdivo (nivolumab) was found to be more effective than Yervoy (ipilimumab) - BMS’CTLA4 inhibitor which is
It has breakthrough status from the FDA. Interim data from that study - reported at the European Society of Medical Oncology (ESMO) conference in September - showed that entrectinib achieved a response rate ... Entrectinib isn’t the only drug in
The data is being presented today at the European Society for Medical Oncology (ESMO) cancer immunotherapy congress in Geneva.
Researchers found Opdivo met its primary endpoint of recurrence-free survival and results were presented at the 2017’s European Society for Medical Oncology (ESMO) based in Madrid, Spain and simultaneously
The two studies reported at the European Society of Clinical Oncology (ESMO) congress in Madrid this week were carried out in high-risk, early-stage patients with stage III BRAF ... Both ipilimumab and the combination of dabrafenib plus trametinib have
The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival
More from news
Approximately 9 fully matching, plus 20 partially matching documents found.
independent organisations such as ESMO, which recently published a paper supporting biosimilars as an option for sustainable cancer treatment.
Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... As the ESMO meeting began, Ipsen received the news that
When I met him at the annual European Society for Medical Oncology (ESMO) meeting in Copenhagen last month he explained how international expansion and oncology were key to Ipsen's plans. ... In Copenhagen, Ipsen's ESMO focus was on the CABOSUN study,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. Summary/transcript. Prof. Matthew Ellis from the Baylor College of Medicine
We talked to Dr Ursula Matulonis of the Dana-Farber Cancer Institute, who co-authored the abstract presented at ESMO.
Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
More from PMHub
Approximately 9 fully matching, plus 0 partially matching documents found.
Transforming healthcare through effective collaboration. Making work to feel proud of.
www.dovetailstrategies.com...